Please Wait...

Herag Frankian

Translation skills

Main profile

Herag Frankian
Program Director, RTSM

Herag Frankian joined Bioclinica at the beginning of 2017 and is currently the Program Director, RTSM responsible for managing the Bioclinica IRT Enablement program, which enables Pharmaceutical/Biotechnology companies as well as CROs to build IRT systems in-house. Herag has 12+ years' experience within the IRT industry in various roles ranging from software validation, project/program management and implementation of study and product standards.

Blogs

Randomization and Trial Supply Management (RTSM) solutions have continually evolved since their original inception in the 1990s. Functionalitiy and requirements have become more complex in nature, as has the need to comply with quality and regulatory standards.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
Bioclinica (2 weeks ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Bioclinica (2 weeks ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Bioclinica (3 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Bioclinica (3 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
Bioclinica (4 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo
Bioclinica (4 weeks ago)